Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia
- 1 January 2003
- journal article
- clinical trial
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 90 (08), 235-244
- https://doi.org/10.1160/th02-11-0283
Abstract
An association has been reported between thrombotic events and the use of L-asparaginase (ASP) in children with acute lymphoblastic leukaemia (ALL). The mechanism for thrombosis is likely related to an acquired antithrombin deficiency. Since a primary prophylaxis using antithrombin concentrates may prevent thrombosis, the PARKAA (Prophylactic Antithrombin replacement in kids with ALL treated with L-asparaginase) study was performed. The objectives of PARKAA were to determine if there was a trend to efficacy and safety of antithrombin treatment as assessed by 1) incidence of thrombosis 2) incidence of bleeding and 3) plasma markers of endogenous thrombin generation as surrogate outcomes for thrombosis. The study was not powered to answer the question of efficacy and safety, but rather to detect a trend. PARKAA was an open, randomised, controlled study in children with ALL being treated with ASP. Children were randomised to receive antithrombin infusions or no antithrombin treatment. All thrombotic events were confirmed using bilateral venography, ultrasound, echocardiography and MRI. The incidence of thrombosis in patients treated with antithrombin was 28% (95% CI 10-46%), compared to 37% (95% CI 24-49%) in the non treated arm. Two minor bleeds occurred in patients in the treated arm, but were not considered to be related to antithrombin. No significant differences were seen in plasma markers by the treatment group. In conclusion, treatment with antithrombin concentrate shows a trend to efficacy and safety. In contrast, there was no difference in surrogate markers for thrombosis. Carefully designed clinical trials are needed to test the efficacy and safety of antithrombin in this population.Keywords
Funding Information
- Canadian Institutes of Health Research ((Grant number: PA 14283))
This publication has 34 references indexed in Scilit:
- Resistance to activated protein C (APCR) in children with acute lymphoblastic leukaemia???the need for a prospective multicentre studyBlood Coagulation & Fibrinolysis, 1995
- Hemostasis in Childhood Acute Lymphoblastic Leukemia: Coagulopathy Induced by Disease and TreatmentSeminars in Thrombosis and Hemostasis, 1995
- L-Asparaginase in Acute Lymphoblastic Leukemia Treatment: The Role of Human Antithrombin III Concentrates in Regulating the Prothrombotic State Induced by TherapyActa Haematologica, 1995
- Antithrombin III infusion suppresses the hypercoagulable state in adult acute lymphoblastic leukaemia patients treated with a low dose of Escherichia coli-asparaginase. A Gimema studyBlood Coagulation & Fibrinolysis, 1994
- Hypercoagulability during l‐asparaginase treatment: the effect of antithrombin III supplementation in vivoBritish Journal of Haematology, 1990
- Lack of pathogenetic role of proteins C and S in thrombosis associated with asparaginase-prednisone-vincristine therapy for leukaemiaBritish Journal of Haematology, 1986
- Thrombosis and hemorrhageduring l-asparaginase therapyThe Journal of Pediatrics, 1983
- A syndrome of thrombosis and hemorrhage complicating l-asparaginase therapy for childhood acute lymphoblastic leukemiaThe Journal of Pediatrics, 1982
- The site in human antithrombin for functional proteolytic cleavage by human thrombinFEBS Letters, 1981
- Preparation and Properties of Serum and Plasma Proteins. IV. A System for the Separation into Fractions of the Protein and Lipoprotein Components of Biological Tissues and Fluids1a,b,c,dJournal of the American Chemical Society, 1946